Compare · ABBV vs QUCY
ABBV vs QUCY
Side-by-side comparison of AbbVie Inc. (ABBV) and Quantum Cyber N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $505.89B, about 11328.9x QUCY ($44.7M).
- Over the past year, ABBV is up 21.2% and QUCY is down 46.5% - ABBV leads by 67.7 points.
- ABBV has been more active in the news (17 items in the past 4 weeks vs 8 for QUCY).
- ABBV has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- AbbVie Inc.
- Quantum Cyber N.V.
- Price
- -
- -
- Market cap
- $505.89B
- $44.7M
- 1M return
- +0.52%
- -48.66%
- 1Y return
- +21.22%
- -46.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 17
- 8
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea.
Latest ABBV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
- EVP, CHIEF OPERATIONS OFFICER Azita Saleki exercised 23,935 shares at a strike of $61.36 and covered exercise/tax liability with 13,481 shares, increasing direct ownership by 5% to 208,248 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
Latest QUCY
- Quantum Cyber N.V. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Quantum Cyber N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Quantum Cyber Reports First Revenue of ~$1.0 Million and Announces $8.0 Million Funding Commitment From Chief Executive Officer David Lazar
- SEC Form 10-Q filed by Quantum Cyber N.V.
- Quantum Cyber N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Highway Holdings Limited Announces Closing of $7.0 Million Strategic Investment by David Lazar and Planned Spin-Off of Its Legacy Business to Existing Shareholders
- Quantum Cyber Publishes Investor Explanatory Materials on Its Quantum Antenna Technology, Including Technical Summary and Companion Video
- Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening
- SEC Form 8-K filed by Mainz Biomed N.V.
- Quantum Cyber Appoints Major General (Ret.) Alberto C. Rosende to Board of Directors